136 related articles for article (PubMed ID: 38814804)
1. Comparison of rituximab efficacy in treatment-naive and refractory inflammatory myopathies: experiences from a tertiary care centre.
Manwatkar A; Naresh K; Mathew J; Nair AV; Goel R; Yadav B; Prakash JAJ; Das JK; Sivadasan A
Rheumatology (Oxford); 2024 May; ():. PubMed ID: 38814804
[TBL] [Abstract][Full Text] [Related]
2. Low-dose rituximab is efficacious in refractory idiopathic inflammatory myopathies.
Janardana R; Amin SN; Rajasekhar L; Pinto B; Kodishala C; Selvam S; Shobha V
Rheumatology (Oxford); 2023 Mar; 62(3):1243-1247. PubMed ID: 35946502
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies.
Ahn GY; Suh CH; Kim YG; Park YB; Shim SC; Lee SH; Lee SS; Bae SC; Yoo DH
J Korean Med Sci; 2020 Sep; 35(38):e335. PubMed ID: 32989931
[TBL] [Abstract][Full Text] [Related]
4. The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature.
Barsotti S; Cioffi E; Tripoli A; Tavoni A; D'Ascanio A; Mosca M; Neri R
Reumatismo; 2018 Jul; 70(2):78-84. PubMed ID: 29976041
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature.
Nalotto L; Iaccarino L; Zen M; Gatto M; Borella E; Domenighetti M; Punzi L; Doria A
Immunol Res; 2013 Jul; 56(2-3):362-70. PubMed ID: 23572427
[TBL] [Abstract][Full Text] [Related]
6. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies.
de Souza FHC; Miossi R; de Moraes JCB; Bonfá E; Shinjo SK
Adv Rheumatol; 2018 Sep; 58(1):31. PubMed ID: 30657080
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis.
Zhen C; Hou Y; Zhao B; Ma X; Dai T; Yan C
Front Immunol; 2022; 13():1051609. PubMed ID: 36578492
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies.
Campochiaro C; Farina N; De Luca G; Batani V; Trignani G; Vignale D; Palmisano A; Matucci-Cerinic M; Dagna L
Arthritis Res Ther; 2024 Apr; 26(1):79. PubMed ID: 38570792
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry.
Couderc M; Gottenberg JE; Mariette X; Hachulla E; Sibilia J; Fain O; Hot A; Dougados M; Euller-Ziegler L; Bourgeois P; Larroche C; Tournadre A; Amoura Z; Mazières B; Arlet P; De Bandt M; Schaeverbeke T; Soubrier M
Rheumatology (Oxford); 2011 Dec; 50(12):2283-9. PubMed ID: 22019807
[TBL] [Abstract][Full Text] [Related]
10. [Long-term rituximab treatment of refractory idiopathic inflammatory myopathy: A report of 3 cases].
Yi WX; Wei CJ; Wu Y; Bao XH; Xiong H; Chang XZ
Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 53(6):1191-1195. PubMed ID: 34916704
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis.
Giannini M; Fiorella ML; Tampoia M; Girolamo F; Fornaro M; Amati A; Lia A; Abbracciavento L; D'Abbicco D; Iannone F
Rheumatology (Oxford); 2021 Mar; 60(3):1234-1242. PubMed ID: 32911543
[TBL] [Abstract][Full Text] [Related]
12. Oral cyclophosphamide in treatment of patients with refractory idiopathic inflammatory myopathies: a retrospective observational study.
Bae S; Charles-Schoeman C
Clin Rheumatol; 2018 Aug; 37(8):2113-2123. PubMed ID: 29971584
[TBL] [Abstract][Full Text] [Related]
13. Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series.
Basnayake C; Cash K; Blumbergs P; Limaye V
Clin Rheumatol; 2015 Feb; 34(2):371-7. PubMed ID: 24337692
[TBL] [Abstract][Full Text] [Related]
14. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies.
Muñoz-Beamud F; Isenberg DA
Clin Exp Rheumatol; 2013; 31(6):896-903. PubMed ID: 24050676
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in the treatment of inflammatory myopathies: a review.
Fasano S; Gordon P; Hajji R; Loyo E; Isenberg DA
Rheumatology (Oxford); 2017 Jan; 56(1):26-36. PubMed ID: 27121778
[TBL] [Abstract][Full Text] [Related]
16. Classification, diagnosis, and management of idiopathic inflammatory myopathies.
Lazarou IN; Guerne PA
J Rheumatol; 2013 May; 40(5):550-64. PubMed ID: 23504386
[TBL] [Abstract][Full Text] [Related]
17. The Efficacy and Safety of Rituximab in Patients with Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease: Case Series.
Jang Y; Yoon HY; Kim HS
J Clin Med; 2023 May; 12(10):. PubMed ID: 37240516
[TBL] [Abstract][Full Text] [Related]
18. Follow-up results of myositis patients treated with H. P. Acthar gel.
Saygin D; Oddis CV; Marder G; Moghadam-Kia S; Nandkumar P; Neiman N; Dzanko S; Koontz D; Aggarwal R
Rheumatology (Oxford); 2020 Oct; 59(10):2976-2981. PubMed ID: 32160301
[TBL] [Abstract][Full Text] [Related]
19. Pulse Dose Methylprednisolone Therapy for Adult Idiopathic Inflammatory Myopathy.
Raghu P; Manadan AM; Schmukler J; Mathur T; Block JA
Am J Ther; 2015; 22(4):244-7. PubMed ID: 25490616
[TBL] [Abstract][Full Text] [Related]
20. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.
Andersson H; Sem M; Lund MB; Aaløkken TM; Günther A; Walle-Hansen R; Garen T; Molberg Ø
Rheumatology (Oxford); 2015 Aug; 54(8):1420-8. PubMed ID: 25740830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
